Automated Insulin for Management of Intrapartum Glycemia

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Mar 12, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring whether automated insulin delivery (AID) systems can help manage blood sugar levels during labor and delivery for pregnant individuals with type 1 diabetes (T1D). The researchers want to find out if using AID systems leads to better blood sugar control for newborns, improves satisfaction with the birth experience, and results in more time spent within the target blood sugar range compared to the traditional method of using intravenous (IV) insulin.

To participate in this study, you must be a pregnant person with a known diagnosis of type 1 diabetes for at least a year, currently using an AID system for at least six months, and at least 34 weeks along in your pregnancy. The study is not open for recruitment yet, and those who are eligible will be randomly assigned to either use the AID system or the standard IV insulin during labor. It's important to know that certain conditions, like planned cesarean deliveries or specific medications, may exclude you from participating.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Known diagnosis of type 1 diabetes ≥ 1 year
• • Current use of commercially available AID system ≥ 6 months
• • Currently pregnant at ≥ 34 weeks
• • Singleton pregnancy
• • English- or Spanish-speaking
• Exclusion Criteria:
• • Planned cesarean delivery
• • Use of medications known to interfere with glucose metabolism
• • Intrauterine fetal demise
• • Physical or psychological disease likely to interfere with the conduct of the study and/or the ability to participate in own healthcare